Walleye Capital LLC Raises Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Walleye Capital LLC increased its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 831.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 364,750 shares of the company’s stock after acquiring an additional 325,585 shares during the quarter. Walleye Capital LLC’s holdings in Syndax Pharmaceuticals were worth $4,822,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of SNDX. Franklin Resources Inc. boosted its holdings in shares of Syndax Pharmaceuticals by 13.4% in the 3rd quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company’s stock worth $34,948,000 after buying an additional 208,043 shares during the last quarter. State Street Corp raised its position in Syndax Pharmaceuticals by 4.1% in the third quarter. State Street Corp now owns 3,770,826 shares of the company’s stock worth $72,588,000 after acquiring an additional 148,491 shares during the period. Barclays PLC boosted its stake in Syndax Pharmaceuticals by 143.4% in the third quarter. Barclays PLC now owns 187,629 shares of the company’s stock valued at $3,612,000 after acquiring an additional 110,535 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Syndax Pharmaceuticals by 3.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,977,082 shares of the company’s stock valued at $38,066,000 after acquiring an additional 66,459 shares during the period. Finally, Simplify Asset Management Inc. increased its stake in shares of Syndax Pharmaceuticals by 20.8% during the 4th quarter. Simplify Asset Management Inc. now owns 147,641 shares of the company’s stock worth $1,952,000 after purchasing an additional 25,456 shares during the last quarter.

Insider Buying and Selling at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CFO Keith A. Goldan sold 3,777 shares of the firm’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $58,543.50. Following the completion of the transaction, the chief financial officer now owns 90,746 shares of the company’s stock, valued at approximately $1,406,563. This trade represents a 4.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Michael A. Metzger sold 13,288 shares of the business’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $205,964.00. Following the sale, the chief executive officer now owns 300,121 shares in the company, valued at approximately $4,651,875.50. This trade represents a 4.24 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 21,683 shares of company stock valued at $336,087. 4.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on SNDX shares. Scotiabank reduced their price objective on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. JPMorgan Chase & Co. raised their price target on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an “overweight” rating in a report on Thursday, March 20th. HC Wainwright reaffirmed a “buy” rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. StockNews.com upgraded Syndax Pharmaceuticals to a “sell” rating in a report on Thursday, April 10th. Finally, Citigroup lowered their price target on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $36.20.

Syndax Pharmaceuticals Stock Down 2.5 %

Shares of SNDX stock opened at $11.05 on Thursday. The firm has a market capitalization of $950.79 million, a price-to-earnings ratio of -3.04 and a beta of 1.28. The stock has a fifty day moving average of $13.42 and a 200 day moving average of $15.20. Syndax Pharmaceuticals, Inc. has a 52 week low of $9.66 and a 52 week high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The firm had revenue of $7.68 million for the quarter, compared to analysts’ expectations of $86.32 million. Equities research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).